Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
Monmouth Medical Center
mi
from
Long Branch, NJ
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
Monmouth Medical Center
mi
from
Long Branch, NJ
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
Lovelace Medical Center - Downtown
mi
from
Albuquerque, NM
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
Lovelace Medical Center - Downtown
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
Duke Women's Cancer Care Raleigh
mi
from
Raleigh, NC
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
Duke Women's Cancer Care Raleigh
mi
from
Raleigh, NC
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
University Pointe
mi
from
West Chester, OH
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
University Pointe
mi
from
West Chester, OH
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
Pocono Medical Center
mi
from
East Stroudsburg, PA
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
Pocono Medical Center
mi
from
East Stroudsburg, PA
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
Adams Cancer Center
mi
from
Gettysburg, PA
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
Adams Cancer Center
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
Cherry Tree Cancer Center
mi
from
Hanover, PA
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
Cherry Tree Cancer Center
mi
from
Hanover, PA
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
Allegheny General Hospital
mi
from
Pittsburgh, PA
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
UPMC Shadyside Hospital
mi
from
Pittsburgh, PA
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
UPMC Shadyside Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
UPMC Jefferson Regional Radiation Oncology
mi
from
Pittsburgh, PA
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
UPMC Jefferson Regional Radiation Oncology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
UPMC-Passavant Hospital
mi
from
Pittsburgh, PA
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
UPMC-Passavant Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
Reading Hospital
mi
from
West Reading, PA
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
Reading Hospital
mi
from
West Reading, PA
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
WellSpan Health-York Hospital
mi
from
York, PA
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
WellSpan Health-York Hospital
mi
from
York, PA
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
Rapid City Regional Hospital
mi
from
Rapid City, SD
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
North Star Lodge
mi
from
Yakima, WA
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
Marshfield Medical Center
mi
from
Marshfield, WI
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
Marshfield Medical Center
mi
from
Marshfield, WI
Click here to add this to my saved trials
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  1/4/2018
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 1/4/2018
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
Using Proton Magnetic Resonance Spectroscopy (MRS) to Predict Response of Vorinostat Treatment in Glioblastoma
Status: Enrolling
Updated:  1/4/2018
Emory University
mi
from
Atlanta, GA
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
Using Proton Magnetic Resonance Spectroscopy (MRS) to Predict Response of Vorinostat Treatment in Glioblastoma
Status: Enrolling
Updated: 1/4/2018
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Phase II Study of 7 Days On/7 Days Off Temozolomide in Patients With High-Grade Glioma
Status: Enrolling
Updated:  1/5/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Phase II Study of 7 Days On/7 Days Off Temozolomide in Patients With High-Grade Glioma
Status: Enrolling
Updated: 1/5/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA
Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Temozolomide (Temodar) for Treatment of Newly Diagnosed Glioblastoma Multiforme and Anaplastic Astrocytoma
Status: Enrolling
Updated:  1/5/2018
Lenox Hill Brain Tumor Center
mi
from
New York, NY
Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA
Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Temozolomide (Temodar) for Treatment of Newly Diagnosed Glioblastoma Multiforme and Anaplastic Astrocytoma
Status: Enrolling
Updated: 1/5/2018
Lenox Hill Brain Tumor Center
mi
from
New York, NY
Click here to add this to my saved trials
NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
A Phase II, Multi-institutional Trial of NOVO-TTF-100A, BCNU and Bevacizumab for GBM in First Relapse
Status: Enrolling
Updated:  1/5/2018
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
A Phase II, Multi-institutional Trial of NOVO-TTF-100A, BCNU and Bevacizumab for GBM in First Relapse
Status: Enrolling
Updated: 1/5/2018
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
A Phase II, Multi-institutional Trial of NOVO-TTF-100A, BCNU and Bevacizumab for GBM in First Relapse
Status: Enrolling
Updated:  1/5/2018
Piedmont Hospital
mi
from
Atlanta, GA
NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
A Phase II, Multi-institutional Trial of NOVO-TTF-100A, BCNU and Bevacizumab for GBM in First Relapse
Status: Enrolling
Updated: 1/5/2018
Piedmont Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
A Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
Status: Enrolling
Updated:  1/10/2018
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
A Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
Status: Enrolling
Updated: 1/10/2018
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
A Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
Status: Enrolling
Updated:  1/10/2018
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
A Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
Status: Enrolling
Updated: 1/10/2018
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
A Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
Status: Enrolling
Updated:  1/10/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
A Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
Status: Enrolling
Updated: 1/10/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
A Phase I/II Evaluation of Vaccination With Type 1 Dendritic Cells Pulsed With Multiple Peptides in the Treatment of HLA-A2 Positive Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated:  1/10/2018
Hillman Cancer Center
mi
from
Pittsburgh, PA
Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
A Phase I/II Evaluation of Vaccination With Type 1 Dendritic Cells Pulsed With Multiple Peptides in the Treatment of HLA-A2 Positive Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated: 1/10/2018
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
Barrow Neurological Institute - St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
Barrow Neurological Institute - St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
University of Arizona Health Network
mi
from
Tucson, AZ
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
University of Arizona Health Network
mi
from
Tucson, AZ
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
City of Hope Cancer Center
mi
from
Duarte, CA
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
City of Hope Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
Kaiser Permanente, Redwood City Medical Center
mi
from
Redwood City, CA
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
Kaiser Permanente, Redwood City Medical Center
mi
from
Redwood City, CA
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
University of California-Davis
mi
from
Sacramento, CA
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
Stanford Cancer Institute, Stanford University
mi
from
Stanford, CA
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
Stanford Cancer Institute, Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
The Hartford Hospital
mi
from
Hartford, CT
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
Yale University Medical Center
mi
from
New Haven, CT
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
Yale University Medical Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
Christiana Care Health Services, Inc
mi
from
Newark, DE
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
Christiana Care Health Services, Inc
mi
from
Newark, DE
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
University of Florida
mi
from
Gainesville, FL
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
Mount Sinai Medical Center, Comprehensive Cancer Center
mi
from
Miami Beach, FL
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
Mount Sinai Medical Center, Comprehensive Cancer Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
Tampa General Hospital
mi
from
Tampa, FL
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated:  1/11/2018
Winship Cancer Institute Emory University School of Medicine
mi
from
Atlanta, GA
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status: Enrolling
Updated: 1/11/2018
Winship Cancer Institute Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials